Keyword: Yescarta (axicabtagene ciloleucel)
A new analysis suggests Novartis could make a decent profit on Kymriah if the cost was just one-third its current price of $475,000.
Thanks to new competition from AbbVie, Gilead's important hep C franchise will have another rough year in 2018.
After ushering Juno through early fundraising, an IPO, clinical setbacks and more, CEO Hans Bishop is set for a big payday.
Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene.
Novartis' Kymriah won regulatory milestones from the FDA and EMA as the company works to hold its leadership position in the budding CAR-T field.
Spark's pioneering Luxturna won FDA approval Tuesday to become the first gene therapy to target disease caused by a specific mutation.
Amid tough times at the drugmaker, Teva is launching an exclusive generic to Gilead Sciences' hep B and HIV antiviral Viread.
Some critics point to the $373,000 price for Gilead's Yescarta as the problem holding up reimbursement, but it may be more nuanced than that.
Novartis is blazing ahead with its bid to take its CAR-T therapy Kymriah into new realms with a double-pronged application in Europe.
Cutting-edge cell therapies from Novartis and Gilead aren't direct rivals for now, but with a new FDA filing, that could change—and soon.